AI identifies most effective climate policies
A brand-new AI analysis of 1,500 climate policies across 41 countries between 1998 and 2022 reveals that only 4% achieved significant emission reductions.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2171 entries already.
Entries by Thomas Gabrielczyk
Vandria closes Series A round at CHF28.3m
Swiss mitophagy specialist Vandria SA has booted its CHF18m Series A financing from December 2023 by further CHF10.3m to push its lead VNA-318 to Phase Ib testing.
Adcendo broadens ADC pipeline in US$1bn biobucks deal
Danish ADC maker Adcendo ApS has licenced the rights to commercialise Multitude Therapeutics Inc’s first-in-class ADCE-T02 globally except the Greater China region.
Emfret presents novel anticoagulant
German biotech spin-out Emfret Analytics GmbH & Co. KG has presented a first in class anticoagulant that helps preventing heart attacks and stroke while showing less adverse effects than approved meds.
BioNTech: ADC study continues with conditions
Good news for BioNTech SE: The safety study of the ADC BNT326/YL202 developed by MediLink Therapeutics, which was suspended by the FDA in mid-June, will continue.
Bavarian Nordic A/S applies for EU label extension of mpox vaccine
Danish vaccine maker Bavarian Nordic A/S has submitted data to the EMA that support label extension of its mpox vaccine imvanex indication to include adolescents 12 to 17 years of age.
Evotec axes 400 jobs worldwide
After the drug discovery specialist Evotec SE lowered its annual forecast and lost almost 75% of its market capitalisation in just eight months, the new CEO, Christian Wojczewski, is taking action and closing non-profitable areas.
Nitrogenases also can fix CO2
Investigating substrate selectivity of nitrogenase enzymes in phototrophic R. capsulatus bacteria, German microbiologist have found one converting CO2 to formiate and methane opening the way to fossil oil-free hydrocarbon synthesis
Sphingotec secures Series C financing
German diagnostics specialist SphingoTec GmbH has closed a €5m Series C financing round led by Think.Health Ventures.
New antibiotic breaks resistance
A Dutch-German resarch team together with Evotec SE have presented a new class of vancomycin derivatives with good safety profile that kill multi-resistant, Gram-positive bugs.